CYP3A4 and rhabdomyolysis: Additionally, a 2012 United Kingdom study found that the interaction of a CYP3A4-metabolized inhibitor with a CYP3A4-metabolized-statin accounted for approximately 30% of patients with statin-induced rhabdomyolysis [139].